SCHEMBL838416

SCHEMBL838416

Cc1c(C)c(S(=O)(=O)Cl)c(C)c2c1OC(C)(C)CC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
TSHR P16473 1/20 0.39
PLG P00747 2/20 0.35
F10 P00742 1/20 0.35
PLAU P00749 1/20 0.35
KLKB1 P03952 1/20 0.35
LMNA P02545 2/20 0.33
HPGD P15428 2/20 0.33
CCR5 P51681 1/20 0.33
F2 P00734 1/20 0.32
IDO1 P14902 2/20 0.32
PSEN1 P49768 4/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
CES2 O00748 1/20 0.31
GMNN O75496 1/20 0.31
TDP2 O95551 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29402889 1.00 CYP1A2 (0.39) CYP1A2CYP3A4PTGS1PTGS2TSHR
Hydrazine SCHEMBL22634091 0.97 CYP1A2 (0.38) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL8294965 0.86 CYP1A2 (0.43) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL112491 0.84 CYP1A2 (0.39) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL4530181 0.84 PTGS1 (0.42) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL8531015 0.84 CYP1A2 (0.39) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL29400649 0.84 CYP1A2 (0.39) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL4434438 0.84 CYP1A2 (0.39) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL29788426 0.84 CYP1A2 (0.39) CYP1A2CYP3A4PTGS1PTGS2TSHR
SCHEMBL17007494 0.84 HSP90AA1 (0.37) CYP1A2CYP3A4PLGPLAULMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966201-A1 THIOSEMICARBAZATES AND USES THEREOF The Feinstein Institutes for Medical Research (US) 2022-03-16 EP claimed
WO-2020227592-A1 THIOSEMICARBAZATES AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2020-11-12 WO claimed
US-20200354318-A1 THIOSEMICARBAZATES AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2020-11-12 US claimed
US-12624002-B2 Dimers for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-05-12 US disclosed
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US disclosed
US-12595233-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-07 US disclosed
US-12590089-B2 Processes for preparing toll-like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2026-03-31 US disclosed
US-20260070894-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-03-12 US disclosed
WO-2025264177-A1 METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2025-12-26 WO disclosed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US disclosed
WO-2025128985-A1 SULFOXIDE AND SULFONE DERIVATIVES OF THIOCARBAZATES AS SYNTHONS FOR AZAPEPTIDES SYNTHESIS AND PROCESS OF USING SAME THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-06-19 WO disclosed
EP-0975600-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS Akzo Nobel N.V. (NL) 2000-02-02 EP disclosed
WO-1999031092-A1 BENZAMINE DERIVATIVES MERCK PATENT GMBH (DE) 1999-06-24 WO disclosed
EP-0906296-A1 PROCESS FOR THE PREPARATION OF CHIRAL KETO-HETEROCYCLES OF BASIC AMINO ACIDS WARNER-LAMBERT COMPANY LLC (US) 1999-04-07 EP disclosed
WO-1998047876-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS AKZO NOBEL N.V. (NL) 1998-10-29 WO disclosed
WO-1997048687-A1 PROCESS FOR THE PREPARATION OF CHIRAL KETO-HETEROCYCLES OF BASIC AMINO ACIDS WARNER-LAMBERT COMPANY (US) 1997-12-24 WO disclosed
EP-0409949-B1 ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS ICI PLC (GB) 1994-05-18 EP disclosed
US-5185452-A Antidiabetic agents; aldose reductase inhibitor IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-09 US disclosed
EP-0409949-A1 ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. ICI PLC (GB) 1991-01-30 EP disclosed
WO-1990008763-A1 ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM CYP1A2 2759/4885CYP3A4 1884/4885PTGS1 2925/4885
US-12624002-B2 Dimers for use in synthesis of peptidomimetics GLUL, ARGLU1, ASNS CYP1A2 4402/4885CYP3A4 3097/4885PTGS1 3055/4885
US-12590089-B2 Processes for preparing toll-like receptor modulator compounds TLR8, MYD88, TLR6 CYP1A2 4588/4885CYP3A4 4572/4885PTGS1 380/4885
US-20260070894-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS NPR1, NGLY1, DDAH1 CYP1A2 3794/4885CYP3A4 1661/4885PTGS1 3510/4885
US-12595233-B2 Thiosemicarbazates and uses thereof TST, THRB, HSPB1 CYP1A2 3031/4885CYP3A4 1872/4885PTGS1 3935/4885
US-20200354318-A1 THIOSEMICARBAZATES AND USES THEREOF TST, ABAT, AADAC CYP1A2 3108/4885CYP3A4 1598/4885PTGS1 4428/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT CYP1A2 2469/4885CYP3A4 763/4885PTGS1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.